SpyGlass Pharma, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2023 | — | $-33.0M | $15.8M |
| FY2024 | — | $-60.5M | $16.3M |
| FY2025 | — | $-98.8M | $96.4M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2023 | — | $-33.0M | $15.8M |
| FY2024 | — | $-60.5M | $16.3M |
| FY2025 | — | $-98.8M | $96.4M |